Загрузка...
Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer
The PI3K/AKT pathway is frequently altered in advanced human prostate cancer mainly through the loss of functional PTEN, and presents as potential target for personalized therapy. Our aim was to determine the therapeutic potential of the pan-AKT inhibitor, AZD5363, in PTEN-deficient prostate cancer....
Сохранить в:
| Опубликовано в: : | Oncotarget |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Impact Journals LLC
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4941290/ https://ncbi.nlm.nih.gov/pubmed/26910118 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7557 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|